Abstract
Recessive Dystrophic Epidermolysis Bullosa (RDEB) is a severe genodermatosis caused by mutations in COL7A1 and characterized by mucocutaneous blistering after minor trauma. Bone marrow–mesenchymal stromal cells (MSCs) have shown therapeutic potential for RDEB patients. Recent preclinical study demonstrated that a systemic infusion of human umbilical cord blood (UCB)-derived nonhematopoietic stem cells correct RDEB murine model. In this study, we wanted to determine the safety and possible clinical efficacy of systemic allogeneic UCB-MSCs therapy for RDEB patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have